# Neovision Capital

Neovision Capital is a Private Equity based in Shanghai, China.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Shanghai, China
- **Region:** Asia
- **Address:** Shanghai, China
- **Assets under management:** Undisclosed
- **Website:** www.neovisioncap.com
- **LinkedIn:** https://www.linkedin.com/company/neovision0

## Regulatory record

- **Reports private funds:** No

## About

Neovision Capital is a principal investment firm focused on early and growth-stage investments in healthcare and pan-entertainment. The firm has made 39 investments, including a Series E investment in CH Biomedical on June 30, 2025. Neovision Capital has facilitated 4 portfolio exits, with Biostar exiting on October 31, 2024.

## Questions

### What investment stages does Neovision Capital cover?

The firm's stated mandate spans the full venture lifecycle, from seed and start-up rounds through expansion and late-stage growth. This positions Neovision Capital to enter at formation and follow on through later fundraises, though specific check-size ranges or stage concentrations have not been publicly disclosed.

### Who leads investment decisions at the firm?

Neovision Capital has not disclosed its GP bench or investment committee structure. No named principals are available through regulatory filings, press coverage, or the firm's own digital presence, leaving the leadership team entirely opaque to outside allocators.

## Related profiles

- [Neo](https://altss.com/profile/neo-ventures)
- [Neowiz Partners](https://altss.com/profile/neowiz-partners)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/neovision-capital

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology